Insights from our recent Know AML webinar, titled ‘Mutation testing in AML: What you need to know’

Know AML hosted a webinar for patients and healthcare professionals (HCPs) on Wednesday, April 23, 2025, titled ‘Mutation testing in AML: What you need to know’. The session was chaired by Professor Charles Craddock, physician at Queen Elizabeth Hospital Birmingham, UK, and Know AML Ambassador; with expert contributions from Professor Gail J. Roboz, physician at Weill Cornell Medicine, New York, US, and Know AML Ambassador; and Ralph Hills, Chair of Know AML, Connecticut, US.

The discussion focused on the vital role of biomarkers in diagnosing acute myeloid leukemia (AML) and informing personalized treatment strategies. The panel also highlighted the importance of empowering patients to engage in meaningful, informed discussions with their physicians, enabling shared decision-making throughout their treatment journey.

Live polls were conducted during the webinar to gather insights into participants’ experiences. A total of 64.7% reported that mutation testing had been done for themselves or the person they care for. Most participants (92.2%) said it took more than a week to receive their mutation test results. Additionally, 55.5% said they had participated in a clinical trial, and 71.4% confirmed that treatment decisions were based on their mutation test results.

The webinar wrapped up with a live Q&A session, allowing attendees to engage directly with the experts. The feedback was highly positive, with 91.6% of participants who completed satisfaction survey agreeing that the content was clear and easy to understand, 92% agreeing that the content addressed the learning objectives, and 79% agreed that the content has increased their confidence in having an open and clear conversation with their physician/patients about mutation testing in AML.

Look out for our enduring content videos available on Know AML and AML Hub soon! If you are interested in supporting any patient webinars, please do contact us.

This independent educational activity is supported by Thermo Fisher Scientific. All content is developed independently by the faculty. The funder is allowed no influence on the content.